The Reduction of Low Density Lipoprotein Cholesterol by Metformin is Maintained with Long-Term Therapy | Zendy

S. G. H. Rains | Zendy; Gregory Wilson | Zendy; W. Richmond | Zendy; R. S. Elkeles | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Reduction of Low Density Lipoprotein Cholesterol by Metformin is Maintained with Long-Term Therapy

Author(s) -

S. G. H. Rains,

Gregory Wilson,

W. Richmond,

R. S. Elkeles

Publication year - 1989

Publication title -

journal of the royal society of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.38

H-Index - 81

eISSN - 1758-1095

pISSN - 0141-0768

DOI - 10.1177/014107688908200213

Subject(s) - metformin , medicine , endocrinology , placebo , cholesterol , insulin , drug , lipoprotein , diabetes mellitus , total cholesterol , pharmacology , alternative medicine , pathology

Changes in serum lipoproteins were studied in 14 non-insulin dependent diabetics on long-term metformin therapy, after 6 weeks' placebo, and again 6 weeks after restarting active drug therapy. Withdrawal of metformin resulted in a rise of fasting blood glucose, HbAl, serum total and low density lipoprotein (LDL) cholesterol. Restarting the drug reversed these changes. Multivariate analysis showed that serum total and LDL cholesterol varied with treatment but not with glycaemic control Metformin can lower serum total and LDL cholesterol in non-insulin dependent diabetics and this effect is maintained long term.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research